HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 173-183

  Kogan, Natalya M ^a   Schlesinger, Michael ^b   Priel, Esther ^c   Rabinowitz, Ruth ^b   Berenshtein, Eduard ^b   Chevion, Mordechai ^b   Mechoulam, Raphael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID DERIVATIVE; CASPASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; HU 331; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CANNABIDIOL; CASPASE 3; CELL CYCLE; DNA BREAKS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; HT29 CELLS; HUMANS; JURKAT CELLS; NAD(P)H DEHYDROGENASE (QUINONE); NUCLEIC ACID CONFORMATION; REACTIVE OXYGEN SPECIES; RECEPTORS, CANNABINOID;

EID: 33846840690     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0039     Document Type: Article

References (42)

1. Begleiter A. Clinical applications of quinone-containing alkylating agents. Front Biosci 2000;5:E153-71.
2. Di Marco A, Cassinelli G, Arcamone F. The discovery of daunorubicin. Cancer Treat Rep 1981;65:3-8.
3. Arcamone F, Cassinelli G. Biosynthetic anthracyclines. Curr Med Chem 1998;5:391-419.
4. Ollinger K, Kagedal K. Induction of apoptosis by redox-cycling quinones. Subcell Biochem 2002;36:151-70.
5. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunomycin. Biochem Pharmacol 1999;57:727-41.
6. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anti-Canc Agents 2003; 3:151-71.
7. Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol 2002;81:504-7.
8. Kogan NM, Rabinowitz R, Levi P, et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 2004; 47:3800-6.
9. Rabinowitz R, Yu Y, Belov E, Shubinsky G, Ben-Bassat H, Schlesinger M. Regulation of the expression of CD45 isoforms in the Farage human B cell lymphoma line and its 10.6.1. subline. Leuk Lymphoma 2001;41: 643-54.
10. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
11. Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-8.
12. Rubnov S, Kashman Y, Rabinowitz R, Schlesinger M, Mechoulam R. Suppressors of cancer cell proliferation from fig (Ficus carica) resin: isolation and structure elucidation. J Nat Prod 2001; 64:993-6.
13. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992;52:797-802.
14. Aflalo E, Seri I, Segal S, Gazit A, Priel E. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action. Cancer Res 1994;54:5138-42.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
16. Ayala-Torres S, Chen Y, Svoboda T, Rosenblatt J, Van Houten B. Analysis of gene-specific DNA damage and repair using quantitative polymerase chain reaction. Methods 2000;22:135-47.
17. Yakes FM, Chen Y, Van Houten B. PCR-based assays for the detection and quantitation of DNA damage and repair, In: Pfeifer GP, editor. Technologies for detection of DNA damage and mutations. New York and London: Plenum Press; 1996. p. 171-84.
18. Sachs RK, Chen PL, Hahnfeldt PJ, Hlatky LR. DNA damage caused by ionizing radiation. Math Biosci 1992;112:271-303.
19. Sanchez C, de Ceballos ML, Gomez del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of CB2 cannabinoid receptor. Cancer Res 2001;61:5784-9.
20. De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 1998;95:8375-80.
21. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999;463: 235-40.
22. Ernster L. DT-diaphorase, a historical review. Chem Scripta 1987;27: 1-13.
23. Lind C, Hochstein P, Ernster L. DT-diaphorase as a quinone reductase: a cellular control device against serniquinone and superoxide radical formation. Arch Biochem Biophys 1992;216:178-85.
24. Radjendirane V, Joseph P, Lee YH, et al. Disruption of the DT-diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 1998;273:7382-9.
25. Lowndes NF, Toh GW. DNA repair: the importance of phosphorylating histone H2AX. Curr Biol 2005; 15:1399-402.
26. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair (Amst) 2004;3: 959-67.
27. Jensen PB, Sehestedf M. DNA Topoisomerase II rescue by catalytic inhibitors. Biochem Pharmacol 1997;54:755-9.
28. Wang HK, Morris-Natschke SL, Lee KS. Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Med Res Rev 1997;17:367-425.
29. Cummings J, Anderson L, Willmott N, Smyth JF. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 1991;27:532-5.
30. Kogan NM. Cannabinoids and cancer. Mini Rev Med Chem 2005;5: 941-52.
31. Kogan NM, Blázquez C, Álvarez L, et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 2006;70:51-9.
32. Broker LE, Kruyt FAE, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005;11:3155-62.
33. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumor cells. Nat Rev Cancer 2004;4:592-603.
34. Sperandio S, Poksay K, de Belle I, et al. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 2004;11:1066-75.
35. Baehrecke EH. Autophagy: dual roles in life and death? Nat Mol Cell Biol 2005;6:505-10.
36. Proskuryakov SY, Gabai VL, Konoplyannikov AG. Necrosis is an active and controlled form of programmed cell death. Biochemistry (Mosc) 2002;67:387-408.
37. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res 2003;283:1-16.
38. Zong WX, Distrworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004; 18:1272-82.
39. Leist M, Jaatela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589-98.
40. Li YZ, Li CJ, Pinto AV, Pardee AB. Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. Mol Med 1999;5:232-9.
41. Thurston LS, Irie H, Tani S, et al. Antitumor agents. 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogues. J Med Chem 1986;29:1547-50.
42. Yoshinari T, Mano E, Arakawa H, et al. Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367. Jpn J Cancer Res 1993;84:800-6.